Rapamycin Response in Tumorigenic and Non-Tumorigenic Hepatic Cell Lines

BACKGROUND: The mTOR inhibitor rapamycin has anti-tumor activity across a variety of human cancers, including hepatocellular carcinoma. However, resistance to its growth inhibitory effects is common. We hypothesized that hepatic cell lines with varying rapamycin responsiveness would show common char...

Descripción completa

Detalles Bibliográficos
Autores principales: Jimenez, Rosa H., Boylan, Joan M., Lee, Ju-Seog, Francesconi, Mirko, Castellani, Gastone, Sanders, Jennifer A., Gruppuso, Philip A.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2756589/
https://www.ncbi.nlm.nih.gov/pubmed/19816606
http://dx.doi.org/10.1371/journal.pone.0007373

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2756589/
https://www.ncbi.nlm.nih.gov/pubmed/19816606
http://dx.doi.org/10.1371/journal.pone.0007373

Ejemplares similares